NeuroSense Therapeutics Ltd. Confirms Favorable Safety and Tolerability of PrimeC in Alzheimer’s Phase 2 Study

NeuroSense Therapeutics Ltd. announced the completion of the safety analysis for their Phase 2 study of PrimeC in Alzheimer's disease. The study, NST-AD-001, indicated a favorable tolerability profile for PrimeC, with no serious adverse events or unexpected safety signals identified. Clinical outcome measures are currently being analyzed alongside biomarker data, with results anticipated in the first quarter of 2026. PrimeC is a novel oral formulation combining ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in neurodegenerative diseases like Alzheimer's and ALS. The company is focused on developing treatments for severe neurodegenerative diseases, addressing a significant unmet medical need.